Loading patent…
AssigneesThe Brigham and Women's Hospital, Inc., Biogen MA Inc.
InventorsRichard S. Blumberg, Timo Rath, Kristi Baker, Adam Mezo, Zachary Taylor, Kevin McDonnell, Rosa Maria Silva Garcia Grenha
Estimating the term…
The invention provided herein includes isolated polypeptides that specifically block the interaction between neonatal Fc receptor (FcRn) and albumin. Blocking the interaction treats diseases and conditions caused by increased amounts of albumin or modified albumin that possesses pathogenic properties wherein it is deemed desirable to decrease albumin levels. Accordingly, also provided are methods of using these isolated polypeptides to treat various diseases and conditions caused by increased amounts of albumin or modified albumin that possesses pathogenic properties. The invention provided herein also includes isolated polypeptides capable of binding to a non-IgG and non-albumin competitive site on an FcRn alpha 3 domain. These can be useful for tracking FcRn without inhibiting IgG or albumin binding or function. Accordingly, the invention also includes methods and systems to track FcRn without inhibiting IgG or albumin binding or function.
A nucleic acid encoding a polypeptide that specifically blocks the interaction between neonatal Fc receptor (FcRn) and albumin, said polypeptide comprising at least one subunit comprising an amino acid sequence at least 90% identical to the amino acid sequence RYFCTKWKHGWCEEVGT (SEQ ID NO:1), wherein the subunit is up to 20 amino acids in length.
An isolated polypeptide capable of binding to a non-IgG and non-albumin competitive site on a FcRn alpha 3 domain comprising the amino acid sequence selected from SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, and SEQ ID NO:6.
Dependencies are inferred from the claim text.